GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019
July 23, 2019 13:27 ET
|
GW Pharmaceuticals plc
LONDON, July 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019
June 04, 2019 06:42 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., June 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the...
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019
May 09, 2019 08:35 ET
|
GW Pharmaceuticals plc
LONDON, May 09, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science,...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019
May 06, 2019 16:01 ET
|
GW Pharmaceuticals plc
- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT - CARLSBAD,...
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
May 06, 2019 16:01 ET
|
GW Pharmaceuticals plc
- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting
May 02, 2019 07:00 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending March 31, 2019 and Host Conference Call on May 6, 2019
April 23, 2019 13:40 ET
|
GW Pharmaceuticals plc
LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercial Officer
April 11, 2019 16:05 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., April 11, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid...
GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M
March 18, 2019 07:30 ET
|
GW Pharmaceuticals plc
CARLSBAD, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018
February 26, 2019 16:01 ET
|
GW Pharmaceuticals plc
– Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the U.S. in November to high awareness and demand – – GW moves to a new fiscal...